Q3 2024 13F Holders as of 9/30/2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value
-
Shares outstanding
-
170M
-
Number of holders
-
258
-
Total 13F shares, excl. options
-
155M
-
Shares change
-
-7.56M
-
Total reported value, excl. options
-
$2.38B
-
Value change
-
-$124M
-
Put/Call ratio
-
0.35
-
Number of buys
-
119
-
Number of sells
-
-126
-
Price
-
$15.38
Significant Holders of ACADIA PHARMACEUTICALS INC - Common Stock, $0.0001 par value (ACAD) as of Q3 2024
316 filings reported holding ACAD - ACADIA PHARMACEUTICALS INC - Common Stock, $0.0001 par value as of Q3 2024.
ACADIA PHARMACEUTICALS INC - Common Stock, $0.0001 par value (ACAD) has 258 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 155M shares
of 170M outstanding shares and own 90.86% of the company stock.
Largest 10 shareholders include BAKER BROS. ADVISORS LP (42.9M shares), VANGUARD GROUP INC (13.8M shares), RTW INVESTMENTS, LP (13.7M shares), BlackRock, Inc. (12.8M shares), STATE STREET CORP (5.97M shares), D. E. Shaw & Co., Inc. (3.5M shares), FRED ALGER MANAGEMENT, LLC (3.19M shares), GEODE CAPITAL MANAGEMENT, LLC (2.88M shares), Palo Alto Investors LP (2.52M shares), and FIRST TRUST ADVISORS LP (2.13M shares).
This table shows the top 258 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.